Month: 2025-03

SINGAPORE, Mar 25, 2025 - (ACN Newswire via SeaPRwire.com) - In today's fast-paced world, many individuals find themselves grappling with overwhelming stress and its accompanying challenges. The constant pressures of modern life can leave individuals feeling mentally and physically drained.Especially in Singapore, the hustle culture and rising cost of living contributes heavily to this. A recent survey found that nearly 90% of Singaporeans experience chronic stress, driven by issues like financial concerns and a general uncertainty about the future. This relentless pace, paired with the constant pressure to meet expectations, continues to take a toll on both mental and physical health, even as the new year begins.Prolonged stress can, however, impact cognitive functions leading to brain fog, memory loss and inflammation, while the digestive system may struggle to keep up with the demands of life. When the mind is overloaded, it becomes difficult to focus, make decisions, or retain information, leading to decreased productivity and increased frustracalention. Furthermore, prolonged stress can disrupt the gut-brain connection, triggering digestive issues such as bloating, indigestion, and inflammation, which hinder the body’s ability to absorb essential nutrients.LAC (pronounced as L-A-C) aims to help individuals navigate these transitions with mindful practices and targeted health solutions. For individuals grappling with cognitive or digestive issues, LAC recommends its BrainSpeed® PS and Probiotic Complex 25 Billion CFU - Daily Support to help support mental and digestive health.Formulated with high phosphatidylserine (PS), LAC BrainSpeed® PS promotes brain health, enhances focus and alertness, and helps individuals cope with stress more effectively, resulting in overall work productivity. This supplement helps to regulate high stress levels, balances mood and promotes cognitive functions for individuals who are seeking mental clarity.With over 25 Billion CFUs of active probiotics and 12 strains of friendly bacteria, Probiotic Complex 25 Billion CFU - Daily Support helps to effectively maintain probiotic levels and boosts the immune system, reducing the risks of inflammation in the gut, maintaining a healthy balance of bacteria in the body.LAC also offers solutions for children to support optimal health and overall well-being. LAC BrainSpeed® Junior is specially formulated with DHA to support cognitive development and mental clarity, allowing children to stay focused in their schools. On the other hand, LAC Probiotic Junior contains 12.5 Billion CFU of Probiotics that strengthens the immune system and absorbs essential nutrients effectively.You may access the high-resolution visuals of the products through the media kit here. Copyright 2025 ACN Newswire via SeaPRwire.com.

- HuaTangNing completed its first full year for reimbursement under the National Reimbursement Drug List (NRDL), with continued expansion in hospital coverage. Compared with the 2023 year, sales volume increased by approximately 740%.- Sales revenue increased by 234% compared with the 2023 year, with cash reserves exceeding RMB 1 billion to fully support future R&D and commercialization activities.- A Phase I clinical study of our second-generation GKA, a once daily oral therapy, successfully completed in the United States. Our dorzagliatin-metformin fixed-dose combination formulation progressed smoothly and our product pipeline continued to advance and expand.- The Mendelian Randomization studies of human genetic data provided scientific evidence to support the exploration of glucokinase activation in diabetic complications and new clinical indications.- Manufacturing capacity of dorzagliatin continued to expand to meet growing market demand.- The establishment of Hua Medicine’s pharmaceutical sales and marketing team resulted in significant sales growth in the first two months of 2025, opening a new model of innovative drug commercialization.SHANGHAI, Mar 28, 2025 - (ACN Newswire via SeaPRwire.com) - Hua Medicine (“the Company”, Hong Kong Stock Exchange Stock Code: 2552) announced the audited full-year results of the Company and its subsidiaries for the year ended December 31, 2024 (the “Reporting Period”), along with the Company’s business progress in 2024 and future business outlook. Hua Medicine has made significant strides in the commercialization of its core product, the glucokinase activator (GKA) dorzagliatin (trade name: HuaTangNing, as well as in R&D innovation and manufacturing capacity optimization, laying a solid foundation for the Company’s long-term sustainable development.Dr. Li Chen, Founder and the Chief Executive Officer of Hua Medicine, stated: “In 2024, HuaTangNing’s market performance was very encouraging. Its inclusion in the NRDL greatly enhanced the accessibility and affordability of this innovative drug, enabling more diabetes patients to benefit. In 2025, Hua Medicine established a pharmaceutical sales and marketing team, and HuaTangNing demonstrated strong growth momentum at the start of the year. With further market expansion and increasing patient awareness, we are confident in HuaTangNing’s market growth.”“Looking ahead, the Company will continue to explore HuaTangNing’s potential in personalized diabetes treatment and diabetes complications globally. By integrating big data and artificial intelligence technologies, we aim to expand our disease areas into immune homeostasis and neural homeostasis. We are confident with the close collaboration of Hua Medicine and its partners across the pharmaceutical R&D, production, and distribution chain, we can enable more patients to access and benefit from Chinese medicines, accelerating progress in realizing our vision ‘China leading pharmaceutical innovation to advance human health.’”Summary of Clinical Research and Operational Progress- Significant Revenue Growth, Strong Market Performance of HuaTangNing, and Positive Patient Feedback- 2024 marked the first full year for which our HuaTangNing was reimbursed under the National Reimbursement Drug List (“NRDL”) in China. Sales revenue increased by 234% to RMB255.9 million for the fiscal year 2024 compared with the same period in 2023. During the fiscal year 2024, HuaTangNing was sold in approximately 2,700 hospitals across China. As of December 31, 2024, Hua Medicine maintained a strong balance sheet with a cash balance of RMB1,139.8 million to support its full-scale commercialization, business development and R&D functions.- Since the launch of HuaTangNing in the fourth quarter of 2022, our pharmacovigilance team has been diligently monitoring the safety of dorzagliatin in the China market, and was recently recognized by the National Adverse Drug Reaction Monitoring Center as a national example for the pharmaceutical industry. As of December 31, 2024, Hua Medicine had monitored approximately 150,000 patients who have been prescribed HuaTangNing, and dorzagliatin has been observed to be safe and well tolerated by patients.- Effective January 1, 2025, Hua Medicine assumed full responsibility for the commercialization of HuaTangNing in China from its former sales and marketing partner, Bayer Healthcare Company Limited (“Bayer”). We recruited Mr. Lu Yu, a seasoned pharmaceutical sales executive with over 20 years of diabetes commercialization experience in China, to lead our sales and marketing efforts.- For the two months ended February 28, 2025, Hua Medicine sold approximately 592,000 packs of HuaTangNing, representing approximately RMB73.2 million in net sales. During the same period in 2024, approximately 202,000 packs of HuaTangNing were sold, representing approximately RMB24.5 million in net sales, The difference represents a significant increase in sales over a period during which the price per pack remained the same. This demonstrates a smooth transition of HuaTangNing’s commercialization in China from Bayer to Hua Medicine, with reinvigorated growth momentum.- Upon the termination of the Exclusive Promotion Service Agreement, the unamortized contact liabilities amounting to RMB1,243,499,000 were released to profit or loss, and will be recognized as a gain in 2025 by the Group. Both parties have confirmed in a signed letter that there are no outstanding matters arising from such termination, nor does either party owe the other party any obligation or liabilities from such separation.- Steady Progress in R&D Innovation, Continuously Enriching Product Pipeline- Hua Medicine made significant headway in preparing the future expansion of our glucokinase-targeted, glucose homeostasis-centered therapy into the international markets, specifically the United States. We successfully completed and announced the results of its single-ascending dose (“SAD”) study in the United States of our second generation GKA (HM-002-1005), in which we validated the feasibility of dorzagliatin as a once daily oral therapy for Type 2 diabetes (“T2D”) patients. We are currently developing the clinical dosage form for advancement of HM-002-1005 in a clinical proof-of-mechanism study.- Hua Medicine also made significant progress in developing fixed-dose combination formulations. The Company has been advancing its dorzagliatin-metformin fixed-dose combination product candidate into commercial dosage development, with process validation expected to be completed in 2025.- Based on human genetic data collected from studies of patients administered with dorzagliatin, the Mendelian Randomization methodology has been applied to predict the beneficial effects of dorzagliatin on related and significant diabetes complications, such as reduction in heart failure, coronary artery disease, memory loss and dyslipidemia. In addition, a separate Mendelian Randomization study provided genetic evidence supporting the causal effects of glucokinase activation on lowering the risk of frailty. These findings suggest that glucokinase activators may aid in the management of frailty and sarcopaenia in people with diabetes. We will continue our research and development efforts to explore new indications.- Through our SENSITIZE 3 clinical study in Hong Kong, Hua Medicine is advancing the potential of dorzagliatin in prediabetes, early treatment and prevention of Type 2 diabetes. In contrast with the approved 75mg dosage form of HuaTangNing, the Company is testing new 25mg and 50mg dosage formulations to explore these potential new indications. The Company is also supporting an investigator-sponsored trial in testing dorzagliatin’s efficacy in treating MODY-2 patients who suffered from genetic mutations that de-activated glucokinase. Early studies in humans by renowned diabetes experts Dr. Juliana Chan and Dr. Linong Ji have indicated the benefit of dorzagliatin in MODY-2 patients by improving their β-cell functions and glycemic control.- Hua Medicine is also advancing the combination of dorzagliatin with GLP-1RA, DPP-IV inhibitors and SGLT-2 inhibitor through combined effects in collecting real-world evidence and proof-of-concept studies in animal models. The synergy between dorzagliatin with these agents has the potential to expand our indication into other diseases in metabolic disorders, such as obesity and MASH. - Hua Medicine will continue our engagement in diabetes prevention, opportunities in longevity and prevention of memory loss and eventually find a new way to increase healthy life span and longevity in humans.- Continued Expansion of Manufacturing Capacity, Plans to Launch Dorzagliatin in New Markets- Hua Medicine continues to invest in expanding its manufacturing capacity to meet anticipated market needs in 2026 and 2027.- Hua Medicine is also finalizing and preparing to submit registration applications for dorzagliatin to launch commercialization in the Macau and Hong Kong markets. We plan to submit both applications in 2025.- Hua Medicine continues to strengthen its intellectual property protection globally. As of December 31, 2024, the Company owned more than 200 granted patents covering its proprietary technology worldwide.Business outlook- There is a great opportunity for dorzagliatin and our 2nd generation GKA in China and the global oral anti-diabetes market. - We will strengthen our own commercialization efforts through hub and spoke development with focus on building up a strong internal sales and medical marketing organization to drive business growth in 2025. This will allow us to rebuild our strong connections directly to the medical community and better promote HuaTangNing in China and surrounding areas.- We continue to invest into digital technology platforms to create synergies across functions and enhance branding opportunities using AI technology.- We are working on the registration of dorzagliatin in HK and Macau region and engage partnerships in Southeastern Asia and Belt and Road nations. In addition, business development work on our 2nd generation GKA in regions with high incidences of obesity will be continued based on the initial success of the SAD study in the United States.Financial SummaryFor the year ended December 31, 2024:- Bank balances and cash position was approximately RMB1,139.8 million.- Total revenue was approximately RMB255.9 million, an increase of approximately 234% compared to the full year of 2023; approximately 2,105,000 packs of HuaTangNing were sold, an increase of approximately 740% compared to the full year of 2023.- Total other income was approximately RMB116.8 million, including approximately RMB95.7 million from the amortization of Bayer milestone income.- Total expenditures for the year was approximately RMB493.6 million, of which R&D expenses accounted for approximately RMB215.1 million.- Loss before tax was approximately RMB250.1 million, which was mainly attributable to the increase of selling expense and research and development expense.Forward-Looking StatementsThis document contains statements regarding Hua Medicine’s future expectations, plans, and prospects for the Company and its products. These forward-looking statements pertain only to events or information as of the date they are made and may change due to future developments. Unless required by law, we are not obligated to update or publicly revise any forward-looking statements or unexpected events after the date of such statements, regardless of new information, future events, or other circumstances. Please read this document carefully and understand that our actual future performance or results may differ materially from expectations due to various risks, uncertainties, or other legal requirements.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing(dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.For more information Hua MedicineWebsite:www.huamedicine.comInvestorsEmail:ir@huamedicine.comMediaEmail:pr@huamedicine.comPress DisclaimerFor accuracy and completeness in context, information related to products marketed in China in this material, especially those identified or required, should comply with documents approved by Chinese regulatory authorities.Additionally, such information should not be interpreted as a recommendation or promotion of any drug or treatment, nor should it replace medical advice from healthcare professionals. For medical-related matters, please consult a healthcare professional. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Mar 28, 2025 - (ACN Newswire via SeaPRwire.com) - Analogue Holdings Limited (“Analogue” or the “Company”, together with its subsidiaries, the “Group”) (stock code: 1977), a leading provider of electrical and mechanical (“E&M”) engineering solutions, and information and communications technology services for smart cities, today announced its annual results for the year ended 31 December 2024 (the “Year” or “FY2024”).Financial Highlights- Contracts-in-hand remained at a high level of HK$11,052.7 million- Revenue rose to HK$6,450.1 million, up 5.2% year-on-year- Adjusted profit attributable to owners of the company recorded HK$206.0 million 1 with a growth of 10.2% 2 year-on-year, excluding a one-off expense and provision- Total dividend for the year amounted to HK4.38 cents per shareChairman Dr Mak Kin Wah said, “Capturing opportunities from shifting market priorities towards intelligent and digital solutions, data centres, environmental engineering and climate solutions, hospitals, infrastructure, and housing, we maintained a high level of contracts-in-hand across the Group’s diverse scope of business, providing a strong underlying foundation for the business over the next two years and beyond; this was notwithstanding the challenges around the world and in Hong Kong during the year.ATAL Tower, our new headquarters, is a significant investment that demonstrates our confidence in the future and our commitment to Hong Kong. We will continue to leverage our expertise and strong financial position to take up additional opportunities in the Hong Kong market, and explore further business development in overseas markets. Our investment in research and development, and innovation will enhance our core strengths and competitiveness. We will tirelessly live up to our motto of ‘We Commit. We Perform. We Deliver.’, ultimately driving our sustainable growth, optimising value for shareholders and other stakeholders, and contributing to the wider community.”Business Review: Building Services- This segment is the largest revenue contributor, with revenue up 5.3% to HK$3,933 million.- The recurring maintenance revenue increased by 40.2% to HK$422 million.- Leadership in the innovative construction technology of Multi-trade Integrated Mechanical, Electrical and Plumbing (“MiMEP”) received a major boost during the year, not only with the award of significant contract for a Grade A office building in Causeway Bay with the highest level of MiMEP application at 85% for a commercial building, but also with the development of our own systematic MiMEP methodologies and solutions.- The “MiMEP Design and Manufacturing Centre” and “MiMEP High Productivity Research Centre” in Zhuhai, as well as other MiMEP manufacturing facilities in Hong Kong, were established to integrate our capabilities in the Greater Bay Area with cutting-edge technology from Hong Kong.Environmental Engineering- The order intake significantly increased by 107.4% to HK$1,514 million, with contracts won for environmental infrastructure needed to enhance climate resilience, environmental protection, sustainability of water supply and waste treatment, and support for public housing and utilities.- The segment actively extended its expert services around the world, including Teresa in the Philippines, Dubai and other parts of the world.Information, Communications and Building Technologies (“ICBT”)- The order intake increased 22.5% to HK$757 million, with contracts-in-hand up 13.8% to HK$959 million.- The segment actively collaborated with leading manufacturers worldwide and in Mainland China to expand its technology reach and deliver cutting-edge solutions in diverse sectors.Lifts and Escalators- There was a significant growth in order intake and revenue, up 48.5% to HK$548 million and up 39.9% to HK$529 million respectively.- The two recently acquired lift companies in the United Kingdom (“UK”) contributed to revenue growth and made progress in the UK business.- The associate in the United States turned from a loss to a profit in FY2024 and made progress in expanding its business into additional cities in the South.For further details of the 2024 Annual Results, please refer to the announcement filed with The Stock Exchange of Hong Kong Limited.Remark:1. Profit attributable to the owners of the Company was HK$135.3 million, including a one-off expense of approximately HK$23.1 million before tax for relocation to the new consolidated headquarters to realise enhanced efficiency and synergy across business units, and a provision for expected credit loss of HK$88.0 million before tax to reflect risks with the recoverability of certain receivables and contract assets held by the Group in relation to certain construction companies.2. When compared with the adjusted profit attributable to owners of the company of HK$186.9 million in FY2023, which excludes a one-off dilution gain before tax upon completion of a private placement by an associate in Mainland China, a gain on disposal of interest before tax in an associate, and a provision before tax in respect of certain contracts in the healthcare sector.About Analogue Holdings LimitedEstablished in 1977, Analogue Holdings Limited is a leading provider of electrical and mechanical (“E&M”) engineering solutions and information and communications technology (“ICT”) services for smart cities, with headquarters in Hong Kong and operations in Macau, Mainland China, the United States and the United Kingdom. Serving a wide spectrum of customers from public and private sectors, the Group provides multi-disciplinary and comprehensive E&M engineering and technology services in four major segments, including Building Services, Environmental Engineering, Information, Communications and Building Technologies (“ICBT”) and Lifts & Escalators.The Group also manufactures and sells Anlev lifts and escalators internationally and has entered into an alliance with Transel Elevator & Electric Inc. (“TEI”), one of the largest independent lifts and escalators companies in New York, the United States. The Group’s associate partner, Nanjing Canatal Data-Centre Environmental Tech Co., Ltd (603912.SS), specialises in manufacturing of precision air conditioners. Copyright 2025 ACN Newswire via SeaPRwire.com.

香港, 2025年3月28日 - (亞太商訊 via SeaPRwire.com) - 領先的機電工程與智慧城市的資訊及通訊科技服務供應商安樂工程集團有限公司（「安樂工程」或「公司」，連同附屬公司統稱（「集團」））（股份代號：1977），今天宣佈截至2024年12月31日止年度（「年內」或「2024財政年度」）的全年業績。財務摘要- 手頭合約總值維持在110.527億港元高位- 收益上升至64.501億港元，按年增加5.2%- 扣除一次性開支及撥備，經調整本公司擁有人應佔溢利為2.06億港元1，按年增加10.2%2- 全年合共派息每股4.38港仙主席麥建華博士表示：「儘管年內全球及香港面臨挑戰，我們憑藉多元化的業務範疇，把握轉趨於智能及數碼解決方案、數據中心、環境工程和氣候解決方案、醫院、基建和房屋等市場機遇，使手頭合約維持高位，為未來兩年及未來的業務發展奠定穩固的基礎。」「新總部安樂工程大廈的啟用，不僅是集團對未來發展的重要投資，亦彰顯我們對香港前景信心滿滿。我們將繼續發揮專業知識和財務優勢，把握更多香港市場的機會，並拓展海外市場的新業務發展。持續投資於研發和創新將增強我們的核心優勢和競爭力。我們將貫切實踐『重承諾、慎履行、獻成果』的座右銘，推動可持續增長，最終為股東和其他持份者創造最佳價值，貢獻社會。」業務回顧：屋宇裝備工程- 該業務板塊對集團的收益貢獻最大，收益上升5.3%，達39.33億港元。- 經常性維修保養收益增加40.2%至4.22億港元。- 在創新建築技術 - 機電裝備合成法（「MiMEP」）的業界領導地位於年內獲得進一步提升，不僅獲得重大合約，為銅鑼灣一幢甲級辦公大樓應用MiMEP達85%，屬商業樓宇的最高水平，更自主研發系統化的MiMEP指引及解決方案。- 在珠海設立「機電裝備合成法設計及建造中心」和「機電裝備合成法高效生產研發中心」，以及於香港設立相關的MiMEP生產設施，旨在將我們於大灣區的生產力與香港的尖端技術相結合。環境工程- 訂單額大幅增長107.4%至15.14億港元，主要由於贏得的合約涉及加強氣候適應力、環境保護、供水及廢物處理的可持續性，以及支持公共房屋及公用事業所需的環境基建。- 積極將其優質服務擴展至全球，包括菲律賓特蕾莎(Teresa)、杜拜及全球其他地區。資訊、通訊及屋宇科技（「ICBT」）- 訂單額增加22.5%至7.57億港元，手頭合約價值上升13.8%至9.59億港元。- 積極與全球及中國內地的領先生產商合作，以擴大技術應用範疇，並為不同領域提供先進技術的解決方案。升降機及自動梯- 訂單額和收益均獲得顯著的增長，分別提升48.5%至5.48億港元和39.9%至5.29億港元。- 近年收購的兩家英國升降機公司對收益增長作出貢獻，並推動英國業務取得進展。- 美國聯營公司於2024財政年度實現轉虧為盈，並將業務進一步擴展至美國南部其他城市。有關2024年度業績詳情，請參閱已呈交香港聯合交易所有限公司的公告。註：1.本公司擁有人應佔溢利為1.353億港元，當中包括因搬遷至新綜合總部以增強業務部門之間的效率及協同效應而產生一次性稅前開支約2,310萬港元，以及預期信貸虧損的稅前撥備8,800萬港元，以反映與若干建築公司有關的應收款項及合約資產可收回性的風險。2.比較2023財政年度經調整本公司擁有人應佔溢利1.869億港元（已撇除一間中國內地聯營公司完成私人配售後一次性稅前攤薄收益、出售於聯營公司權益的稅前收益及就若干醫療保健業務合約的稅前撥備）。關於安樂工程集團有限公司安樂工程集團有限公司成立於1977年，為領先的機電工程與智慧城市的資訊及通訊科技服務供應商，總部設於香港，業務遍及澳門、中國內地、美國及英國。本集團為不同行業，包括公共和私營的客戶提供跨專業、綜合性的機電工程和技術服務，涵蓋屋宇裝備工程、環境工程、資訊、通訊及屋宇科技（「ICBT」），以及升降機及自動梯等四大業務板塊。本集團同時製造及向全球銷售Anlev升降機及自動梯，並與美國紐約最大獨立升降機及自動梯公司之一Transel Elevator & Electric Inc.（「TEI」）達成夥伴關係。本集團的聯營公司南京佳力圖機房環境技術股份有限公司（603912.SS）專門製造精密空調設備。 Copyright 2025 亞太商訊 via SeaPRwire.com.